11月24日，华森制药大宗交易成交14.1万股，成交额200.5万元，占当日总成交额的5.33%，成交价14.22 元，较市场收盘价16.09元折价11.62%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | | | | | 2025-11-24 | 002907 | 华森制药 | 14.22 | 14.10 | | 200.50 华泰证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司广东分公司 | 公司宜都长江大道 | | | | | | | | | 证券营业部 | ...

11月24日，华森制药盘中上涨2.09%，截至14:04，报16.13元/股，成交2832.63万元，换手率0.59%，总 市值67.36亿元。 资金流向方面，主力资金净流入48.16万元，大单买入341.90万元，占比12.07%，卖出293.73万元，占比 10.37%。 华森制药今年以来股价涨24.89%，近5个交易日跌4.27%，近20日跌5.06%，近60日跌12.50%。 今年以来华森制药已经4次登上龙虎榜，最近一次登上龙虎榜为8月1日，当日龙虎榜净买入8508.37万 元；买入总计1.64亿元 ，占总成交额比21.43%；卖出总计7869.44万元 ，占总成交额比10.30%。 资料显示，重庆华森制药股份有限公司位于重庆市渝北区黄山大道中段89号，成立日期1996年11月4 日，上市日期2017年10月20日，公司主营业务涉及一家集药品研发、生产、销售于一体的综合型制药企 业,业态覆盖医药工业、医药商业及医药零售。主营业务收入构成为：耳鼻喉科用药34.24%，消化系统 用药23.16%，精神神经系统用药18.37%，医药商业15.02%，其他领域用药7.76%，其他(补充)1.36%， 医药零售 ...

Core Viewpoint - Huason Pharmaceutical announced the completion of domestic production registration for its product, Apselaziglan Tablets, with the National Medical Products Administration [2] Group 1 - The company has recently checked the National Medical Products Administration website and confirmed the registration of Apselaziglan Tablets [2] - The registration includes an application for the product's instructions to be adapted for elderly users [2] - The registration information has been publicly announced on the National Medical Products Administration website [2]

Group 1: Legal and Regulatory Issues - The National Healthcare Security Administration disclosed a bribery case involving Huang Mouyun, who was found guilty of bribing multiple healthcare professionals to increase sales of a traditional Chinese medicine product [1][2] - Huang Mouyun paid a total of 1.9263 million yuan in bribes to 15 doctors at a local hospital to secure sales, with the product achieving over 10 million yuan in sales since December 2018 [1][2] - The court ruled that Huang Mouyun's actions constituted bribery of non-state personnel, and he may receive a lighter sentence due to his confession [2] Group 2: Pharmaceutical Developments - Huason Pharmaceutical announced that its product, Amlodipine Besylate Tablets, has completed domestic production registration, aimed at enhancing market competitiveness amid an aging population [1] - Fosun Pharma's subsidiary has had its PD-1 monoclonal antibody, used for gastric cancer treatment, included in the breakthrough therapy designation, marking a significant advancement in cancer treatment options [3] - Tianyi Medical received a medical device registration certificate for its blood dialysis concentrate, which is intended for patients with acute and chronic renal failure [4] Group 3: Clinical Research and Results - Innovent Biologics reported that its drug, Ma Shidu Peptide, achieved a weight reduction of up to 20.1% in obese patients during a Phase III clinical trial, with significant improvements in various health metrics compared to the placebo group [5][6] - The trial involved 462 participants, with the Ma Shidu Peptide group showing an average weight loss of 18.55% after 60 weeks, while the placebo group only lost 3.02% [6] Group 4: Corporate Governance - Changchun High-tech announced a change in the shareholding structure of its controlling shareholder, which will not affect the company's operations or control [4][5] - Guangji Pharmaceutical's independent director, Guo Wei, resigned due to personal reasons, which may impact the board's composition and the presence of accounting professionals [8]

Core Viewpoint - The company has completed the domestic production drug filing for Apsaglar (甲磺酸雷沙吉兰片) to address the aging population trend, enhancing product usability and readability through larger print and electronic instructions [1] Group 1 - The company has received approval from the National Medical Products Administration for the domestic production of Apsaglar [1] - The initiative aims to improve the readability and usability of product information for elderly consumers [1] - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for aging-friendly reforms, reflecting its commitment to social responsibility [1] Group 2 - This move is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through these innovations [1]

Core Viewpoint - The company has completed the domestic production registration of Apsaglarin tablets, which is a response to the aging population trend and aims to enhance the readability and usability of product information [1] Group 1: Product Registration and Compliance - The company has received approval from the National Medical Products Administration for the domestic production registration of Apsaglarin tablets [1] - The registration includes an application for an age-friendly product information leaflet, which features larger font sizes and the introduction of an electronic version [1] Group 2: Social Responsibility and Innovation - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for age-friendly reform, reflecting its commitment to social responsibility [1] - This initiative demonstrates the company's efforts in product and service innovation aimed at the elderly population [1] Group 3: Market Opportunities - The completion of the registration is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through this initiative [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-086 重庆华森制药股份有限公司 药 品 通 用 名 称：甲磺酸雷沙吉兰片 备 案 号：渝备 2025047469 关于公司产品完成境内生产药品备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品甲磺酸雷沙吉兰片完成 境内生产药品备案（药品说明书适老化申请），并于国家药监局网站公示备案信 息。现将相关情况公告如下： 一、药品基本信息 （一）药品说明书适老化申请 1.甲磺酸雷沙吉兰片 药 品 批 准 文 号 / 原 料 药 登 记 号 ：国药准字 H20243081 上 市 许 可 持 有 人：重庆华森制药股份有限公司 上市许可持有人地址：重庆市荣昌区工业园区 二、药品其他相关情况 甲磺酸雷沙吉兰片为国家医保乙类药，是公司自主研发的仿制药，公司是国 内第四家仿制药获批厂家，该药品质量和疗效等同原研产品。此外，公司自产该 品种原料药，为原料药制剂一体化品种，详见公司于 2024 ...

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has announced that its product, Apsaglar (Apsaglar tablets), has completed the domestic production drug filing and the application for the aging-friendly drug label, which has been publicly disclosed on the National Medical Products Administration (NMPA) website [1] Group 1 - The product Apsaglar has received approval for domestic production drug filing [1] - The application for aging-friendly drug labeling has been successfully submitted [1] - The filing information has been officially published on the NMPA website [1]

Group 1 - The company Huason Pharmaceutical (002907.SZ) has announced that its product, Apsa-Rasagiline Tablets, has completed the domestic production drug filing with the National Medical Products Administration (NMPA) [1] - The filing includes an application for the drug's instructions to be adapted for elderly patients, which indicates a focus on improving accessibility for this demographic [1] - The registration information has been publicly disclosed on the NMPA's website, enhancing transparency regarding the company's product status [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has completed the domestic production registration of its product, Amlodipine Besylate Tablets, which includes an elderly-friendly drug instruction manual. This registration aims to enhance readability and usability, addressing the aging population trend, and is expected to improve market competitiveness and open new market opportunities, although it will not have a significant short-term impact on the company's performance [1]. Group 1 - The product Amlodipine Besylate Tablets is classified as a Category B drug under the national medical insurance system [1]. - The drug is indicated for the treatment of primary Parkinson's disease, both as a standalone treatment and as an adjunct to Levodopa [1]. - The registration includes both a simplified paper version and a complete electronic version of the drug instruction manual [1]. Group 2 - The registration is part of the company's strategy to respond to the aging population trend [1]. - The expected outcome of this registration is to enhance the product's market competitiveness [1]. - The company anticipates that this move will help in exploring new market opportunities [1].